WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

Inicio・Lista de Acciones・Compass Pathways Plc ADR

Compass Pathways Plc ADR

Cerrado

9.56 4.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.35

Máximo

9.56

Métricas clave
By Trading Economics
Ingresos	44M -94M
Empleados	156
EBITDA	91M -46M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+127.87% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	670M 1.3B
Apertura anterior	4.74
Cierre anterior	9.56

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

3.645 / 4.0539 Soporte y Resistencia

Compass Pathways Plc ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

Intertek Group Rejects EQT's Revised Offer

24 abr 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Scoring the Cook Era -- Barrons.com

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:09 UTC

Ganancias

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 abr 2026, 19:48 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 abr 2026, 19:22 UTC

Ganancias

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 abr 2026, 19:06 UTC

Ganancias

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 abr 2026, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 abr 2026, 18:30 UTC

Adquisiciones, fusiones, absorciones

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 abr 2026, 18:28 UTC

Adquisiciones, fusiones, absorciones

Intertek Rejects Revised EQT Offer

24 abr 2026, 18:12 UTC

Charlas de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 abr 2026, 18:06 UTC

Charlas de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 abr 2026, 17:42 UTC

Ganancias

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 abr 2026, 17:28 UTC

Ganancias

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 abr 2026, 17:28 UTC

Charlas de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 abr 2026, 17:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 abr 2026, 17:11 UTC

Charlas de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 abr 2026, 17:09 UTC

Charlas de Mercado

Ganancias

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:06 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 abr 2026, 16:51 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 abr 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

24 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Compass Pathways Plc ADR previsión

Precio Objetivo

By TipRanks

127.87% repunte

Estimación a 12 Meses

Media 21.83 USD 127.87%

Máximo 70 USD

Mínimo 8 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compass Pathways Plc ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Compass Pathways Plc ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.645 / 4.0539Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.